GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT01934101
- Locations
- 🇬🇧
GSK Investigational Site, Belfast, United Kingdom
Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis
- Conditions
- Sinusitis, Acute
- Interventions
- Drug: Amoxicillin-Potassium Clavulanate Combination
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT01934231
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
- Conditions
- Gastroparesis
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 91
- Registration Number
- NCT01934192
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT01929863
- Locations
- 🇺🇸
GSK Investigational Site, Miami, Florida, United States
A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 81
- Registration Number
- NCT01929317
- Locations
- 🇯🇵
GSK Investigational Site, Shizuoka, Japan
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
- Conditions
- Alopecia
- Interventions
- Drug: GI198745 0.1 mgDrug: GI198745 0.5 mg
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT01929330
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT01928940
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea
- Conditions
- Diphtheria-Tetanus-acellular Pertussis Vaccines
- Interventions
- Biological: BoostrixOther: Safety data collection
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 682
- Registration Number
- NCT01929291
- Locations
- 🇰🇷
GSK Investigational Site, Suwon-si, Korea, Republic of
Tafenoquine Thorough QTc Study in Healthy Subjects
- Conditions
- Malaria, Vivax
- Interventions
- Drug: Placebo for moxifloxaxin
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 260
- Registration Number
- NCT01928914
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: GSK2647544 oralDrug: [18F]GSK2647544 IV bolus
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT01924858
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom